296 related articles for article (PubMed ID: 20043696)
21. Evaluating scoring functions for docking and designing beta-secretase inhibitors.
Katharine Holloway M; McGaughey GB; Coburn CA; Stachel SJ; Jones KG; Stanton EL; Gregro AR; Lai MT; Crouthamel MC; Pietrak BL; Munshi SK
Bioorg Med Chem Lett; 2007 Feb; 17(3):823-7. PubMed ID: 17107793
[TBL] [Abstract][Full Text] [Related]
22. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
Yang W; Lu W; Lu Y; Zhong M; Sun J; Thomas AE; Wilkinson JM; Fucini RV; Lam M; Randal M; Shi XP; Jacobs JW; McDowell RS; Gordon EM; Ballinger MD
J Med Chem; 2006 Feb; 49(3):839-42. PubMed ID: 16451048
[TBL] [Abstract][Full Text] [Related]
23. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1.
Stachel SJ; Coburn CA; Rush D; Jones KL; Zhu H; Rajapakse H; Graham SL; Simon A; Katharine Holloway M; Allison TJ; Munshi SK; Espeseth AS; Zuck P; Colussi D; Wolfe A; Pietrak BL; Lai MT; Vacca JP
Bioorg Med Chem Lett; 2009 Jun; 19(11):2977-80. PubMed ID: 19409780
[TBL] [Abstract][Full Text] [Related]
24. BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character.
Clarke B; Demont E; Dingwall C; Dunsdon R; Faller A; Hawkins J; Hussain I; MacPherson D; Maile G; Matico R; Milner P; Mosley J; Naylor A; O'Brien A; Redshaw S; Riddell D; Rowland P; Soleil V; Smith KJ; Stanway S; Stemp G; Sweitzer S; Theobald P; Vesey D; Walter DS; Ward J; Wayne G
Bioorg Med Chem Lett; 2008 Feb; 18(3):1017-21. PubMed ID: 18166458
[TBL] [Abstract][Full Text] [Related]
25. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design.
Park H; Lee S
J Am Chem Soc; 2003 Dec; 125(52):16416-22. PubMed ID: 14692784
[TBL] [Abstract][Full Text] [Related]
26. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
Iserloh U; Wu Y; Cumming JN; Pan J; Wang LY; Stamford AW; Kennedy ME; Kuvelkar R; Chen X; Parker EM; Strickland C; Voigt J
Bioorg Med Chem Lett; 2008 Jan; 18(1):414-7. PubMed ID: 18023580
[TBL] [Abstract][Full Text] [Related]
27. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
Edwards PD; Albert JS; Sylvester M; Aharony D; Andisik D; Callaghan O; Campbell JB; Carr RA; Chessari G; Congreve M; Frederickson M; Folmer RH; Geschwindner S; Koether G; Kolmodin K; Krumrine J; Mauger RC; Murray CW; Olsson LL; Patel S; Spear N; Tian G
J Med Chem; 2007 Nov; 50(24):5912-25. PubMed ID: 17985862
[TBL] [Abstract][Full Text] [Related]
28. Molecular docking and structure-activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors.
Xu W; Chen G; Zhu W; Zuo Z
Bioorg Med Chem Lett; 2010 Nov; 20(21):6203-7. PubMed ID: 20850315
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
[TBL] [Abstract][Full Text] [Related]
30. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase.
Congreve M; Aharony D; Albert J; Callaghan O; Campbell J; Carr RA; Chessari G; Cowan S; Edwards PD; Frederickson M; McMenamin R; Murray CW; Patel S; Wallis N
J Med Chem; 2007 Mar; 50(6):1124-32. PubMed ID: 17315857
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.
Sealy JM; Truong AP; Tso L; Probst GD; Aquino J; Hom RK; Jagodzinska BM; Dressen D; Wone DW; Brogley L; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Dappen MS; Toth G; Pan H; Ruslim L; Miller J; Bova MP; Sinha S; Quinn KP; Sauer JM
Bioorg Med Chem Lett; 2009 Nov; 19(22):6386-91. PubMed ID: 19811916
[TBL] [Abstract][Full Text] [Related]
32. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
33. Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors.
Wångsell F; Nordeman P; Sävmarker J; Emanuelsson R; Jansson K; Lindberg J; Rosenquist S; Samuelsson B; Larhed M
Bioorg Med Chem; 2011 Jan; 19(1):145-55. PubMed ID: 21183353
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).
Stachel SJ; Coburn CA; Steele TG; Jones KG; Loutzenhiser EF; Gregro AR; Rajapakse HA; Lai MT; Crouthamel MC; Xu M; Tugusheva K; Lineberger JE; Pietrak BL; Espeseth AS; Shi XP; Chen-Dodson E; Holloway MK; Munshi S; Simon AJ; Kuo L; Vacca JP
J Med Chem; 2004 Dec; 47(26):6447-50. PubMed ID: 15588077
[TBL] [Abstract][Full Text] [Related]
35. Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors.
Chiriano G; Sartini A; Mancini F; Andrisano V; Bolognesi ML; Roberti M; Recanatini M; Carloni P; Cavalli A
Chem Biol Drug Des; 2011 Apr; 77(4):268-71. PubMed ID: 21244641
[TBL] [Abstract][Full Text] [Related]
36. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Cole DC; Stock JR; Chopra R; Cowling R; Ellingboe JW; Fan KY; Harrison BL; Hu Y; Jacobsen S; Jennings LD; Jin G; Lohse PA; Malamas MS; Manas ES; Moore WJ; O'Donnell MM; Olland AM; Robichaud AJ; Svenson K; Wu J; Wagner E; Bard J
Bioorg Med Chem Lett; 2008 Feb; 18(3):1063-6. PubMed ID: 18162398
[TBL] [Abstract][Full Text] [Related]
37. Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement.
Steele TG; Hills ID; Nomland AA; de León P; Allison T; McGaughey G; Colussi D; Tugusheva K; Haugabook SJ; Espeseth AS; Zuck P; Graham SL; Stachel SJ
Bioorg Med Chem Lett; 2009 Jan; 19(1):17-20. PubMed ID: 19036583
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors.
Hanessian S; Shao Z; Betschart C; Rondeau JM; Neumann U; Tintelnot-Blomley M
Bioorg Med Chem Lett; 2010 Mar; 20(6):1924-7. PubMed ID: 20172717
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.
Bowers S; Xu YZ; Yuan S; Probst GD; Hom RK; Chan W; Konradi AW; Sham HL; Zhu YL; Beroza P; Pan H; Brecht E; Yao N; Lougheed J; Tam D; Ren Z; Ruslim L; Bova MP; Artis DR
Bioorg Med Chem Lett; 2013 Apr; 23(7):2181-6. PubMed ID: 23465612
[TBL] [Abstract][Full Text] [Related]
40. An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme.
Kornacker MG; Lai Z; Witmer M; Ma J; Hendrick J; Lee VG; Riexinger DJ; Mapelli C; Metzler W; Copeland RA
Biochemistry; 2005 Aug; 44(34):11567-73. PubMed ID: 16114893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
